Stop Opioid Overdoes Naloxone
Fentanyl Drives Fatal Overdoses to Over 107,000 Annually in the U.S. - Healthcare Providers' Effort to Fight Back
August 24, 2022 09:00 ET | Cordant Health Solutions
PORTLAND, Ore., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cordant Health Solutions®, a leader in providing innovative tools for addiction treatment programs, is partnering with addiction treatment providers...
ZIMHI Device.png
US WorldMeds Launches ZIMHIDirect.com
July 05, 2022 11:32 ET | US WorldMeds
LOUISVILLE, Ky., July 05, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds) announces ZIMHI™ (naloxone HCL Injection) 5mg/0.5mL is now available for ordering by public interest groups through the...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
June 01, 2022 08:00 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Global Suboxone Market
Global Global Suboxone Market Analysis/Forecast Report 2022-2030: Increasing Product Launches is Expected to Drive Growth
May 24, 2022 06:49 ET | Research and Markets
Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
December 01, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals logo
Adamis Receives FDA Approval for ZIMHI
October 18, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...
Adamis Pharmaceuticals logo
Adamis Provides Update on ZIMHI™
June 09, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
May 17, 2021 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
May 17, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
May 12, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...